Tarja Stenvall, President and Chief Executive Officer, Bavarian Nordic

In a sexual health clinic on an ordinary weekday, a nurse opens the vaccine fridge, checks the display and writes a temperature in a log that nobody outside the building will ever read. The task takes seconds. It is the last link in a chain that begins months earlier in a commercial team at the UK Health Security Agency, and this week that chain was given a longer and steadier run. UKHSA has awarded the Danish manufacturer Bavarian Nordic a four-year contract to supply MVA-BN, the non-replicating vaccine licensed in Britain as Imvanex, which protects against mpox and smallpox. The agreement gives the agency a more settled arrangement for securing an essential vaccine, while placing a longer-term responsibility on the manufacturer to maintain supply.

The details are thin. Neither the value, the number of doses nor the delivery calendar has been disclosed, so taxpayers cannot yet judge value for money and readers should be wary of any figure that appears in commentary. What is known is that deliveries will be scheduled across the term and that the contract carries optional flexibility provisions. That structure is the news. Health security purchasing has often been reactive, with orders placed in a hurry once a threat is visible and every other buyer is already at the supplier's door. A scheduled arrangement with room to adjust lets UKHSA buy calmly and gives the manufacturer a demand signal it can plan against. It also gives the agency a longer period in which to consider how stock levels should respond as the threat from infectious diseases changes.

The recent past explains why that matters. In September 2024 the government ordered more than 150,000 doses in anticipation of clade I mpox, within days of the manufacturer announcing that it would prioritise supply to the Democratic Republic of the Congo, where an outbreak was growing. Wealthy governments and humanitarian procurers were drawing on a single production line, and the World Health Organization's approval of the vaccine that same week widened the queue further. A customer with deliveries already agreed is better placed in such a queue than one arriving with an urgent request. The European Commission reached a similar view in its own four-year framework for up to eight million doses, so Britain is moving in step with its neighbours. The wider lesson is that access to vaccines can become a question of timing as much as purchasing power when several countries face the same public health emergency.

For patients, the relevant programme is the routine mpox vaccination offer recommended by the Joint Committee on Vaccination and Immunisation in November 2023. It is delivered through sexual health services to people at highest risk, with provision for certain healthcare workers and close contacts of confirmed cases. A secure supply makes that offer credible. Clinicians can plan sessions around known stock, and fewer doses are wasted when consignments arrive on a predictable rhythm. Public confidence in a targeted vaccination offer also depends on its being available when people turn up. Turning someone away for lack of stock costs more in trust than any line in a budget. The agreement should therefore make it easier for services to plan ahead, although the practical benefit will depend on how effectively vaccine supplies are distributed across the country.

The implications for NHS leaders are now clear and practical. A stockpile counts only when it reaches an arm, and delivery rests on a part of the system that receives little attention. Sexual health services are commissioned by local authorities from the public health grant, and they work under sustained pressure from demand for testing and treatment. Vaccinating at pace during a cluster of cases requires staff time, appointment capacity, cold chain storage and data systems that record who has been offered what. The contract gives the centre a firm footing. Integrated care boards and local commissioners would be wise to ask for the delivery schedule in confidence, so that clinic capacity is matched to expected stock, and ministers should be ready to say how a surge in demand would be funded. Without that preparation, a reliable supply agreement could still leave local services struggling to translate available doses into timely vaccinations.

The supply side deserves equal care. MVA-BN is described as the only vaccine available for the UK's routine mpox programme, which makes one manufacturer a dependency however reliable the partnership has been. The flexibility provisions suggest UKHSA has considered this, and an agreement of this length is a sound basis for discussing buffer stocks and a contingency plan for any interruption at the plant. Those conversations are far easier to hold inside a settled contract than in the middle of a shortage. They also place responsibility on Bavarian Nordic to ensure that its manufacturing and distribution arrangements can meet the demands of a government customer over several years, including when international demand rises unexpectedly.

That responsibility now sits under the leadership of Tarja Stenvall, Bavarian Nordic's President and Chief Executive Officer, who took up the role on 15 October 2026, shortly before the UK contract was announced. She brings more than two decades of pharmaceutical industry experience, having held senior positions at Sanofi, AstraZeneca and Pfizer. Her background is particularly relevant to the agreement because it includes leadership of Sanofi's vaccine business in Latin America, where she secured what Bavarian Nordic described as the company's largest global private-public partnership. She most recently led Sanofi's global diabetes and cardiovascular diseases franchise, overseeing a portfolio with a value of €10 billion. Her experience spans vaccine markets, international commercial operations and the management of large pharmaceutical businesses. On taking the Bavarian Nordic role, she identified the company's scientific foundations, global manufacturing capabilities and established supply chain as important strengths. Those capabilities will matter as the manufacturer works to fulfil its four-year commitment to the UK. Stenvall's appointment does not establish that she personally negotiated the agreement, but she now leads the company responsible for delivering it. The challenge for her leadership will be to turn the manufacturer's production and commercial capacity into dependable supply for government customers.

For life sciences and health-tech businesses, the signal is worth reading closely. Government as a customer is often described as slow and unpredictable. Here a department has offered a manufacturer four years of scheduled demand, which is the kind of commitment that justifies keeping capacity ready between outbreaks. Stenvall's experience in international vaccine markets gives her a relevant perspective on the importance of long-term relationships between manufacturers and public authorities. If the same approach extended to other countermeasures, from antivirals to diagnostics, the UK would offer investors something the sector has long requested, a buyer that behaves consistently. Predictability could help manufacturers plan production and investment, although the wider success of such arrangements will depend on transparent procurement and a willingness to avoid excessive reliance on individual suppliers.

The mpox contract is modest in headline terms and worth more than its coverage suggests. It shows that UKHSA can buy for the long term, and it sets a standard that the rest of the system can reasonably be asked to meet. The nurse with the temperature log will do her part. Whether the next four years deliver on the promise depends on whether everyone around her has been given the same certainty.